Pharmacist's Letter Canada | Convenient Monthly Updates + CE

March 2026 Issue

Shed Light on Oral Semaglutide for Cardiovascular Protection

Oral semaglutide (Rybelsus) is now approved to prevent major adverse CV events in certain high-risk adults with type 2 diabetes...

Resources

Algorithm: Stepwise Treatment of Type 2 Diabetes
Chart: Diabetes Medications: Cardiovascular and Kidney Impact

Put Meds for Uterine Fibroids in Perspective

Up to 80% of females develop uterine fibroids over their lifetime...

Avoid Common Blood Pressure Measurement Errors

Blood pressure is often measured incorrectly...

Lift the Fog Around Fibromyalgia Treatment

You’re in a key position to help manage fibromyalgia symptoms such as pain, mood, and sleep issues...

GO TO FULL ISSUE

CE & Training

INTERACTIVE SELF-STUDY CE: Identification and Management of Drug Allergies

CE-IN-THE-LETTER: Pharmacist's Letter Canada March 2026

LIVE CE: Pharmacy Essential Updates March 2026

PODCAST CE: Clinical Capsules - What's New in Acute Sinusitis: Antibiotics vs. Watchful Waiting

GO TO CE & TRAINING ORGANIZER >

Featured Clinical Resources

GLP-1 and GIP/GLP-1 Receptor Agonists interactive chart

Inhalation Medications for Asthma (Canada)

Stepwise Treatment of Asthma j12 Years and Older

Group Purchases & Pricing

Pharmacist’s Letter Canada is eligible for bulk discounts. Easily manage staff access and customize CE & training assignments. Bundle with other products for significant savings. Request information